prostate cancer
Conditions
Interventions
prostate cancer patient with neoadjuvant hormonal therapy:none
prostate cancer patient without neoadjuvant hormonal therapy:none
Sponsors
West China hospital, Sichuan University
Eligibility
Sex/Gender
Male
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients in the high-risk prostate cancer (HRPCa) or locally advanced prostate cancer (LAPCa) stages who have received preoperative NHT (Neoadjuvant Hormonal Therapy); 2. Serum testosterone levels have reached castration levels; 3. Consent to participate in the clinical trial and have signed an informed consent form; 4. Expected life expectancy >3 months.
Exclusion criteria
Exclusion criteria: 1. History of autoimmune diseases or the need for systemic corticosteroid use; 2. Presence of severe heart, lung, liver, kidney, or hematological diseases; 3. Previous treatment with immune checkpoint inhibitors or neoadjuvant radiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease Control Rate;Pathological Response Rate; | — |
Countries
China
Contacts
Public ContactQiang Dong
West China hospital, Sichuan University
Outcome results
None listed